Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 373.4 g/mol |
---|---|
Molecular Formula | C21H15N3O4 |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 2 |
Exact Mass | 373.10625597 g/mol |
Monoisotopic Mass | 373.10625597 g/mol |
Topological Polar Surface Area | 98.7 A^2 |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 912 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Exjade |
PubMed Health | Deferasirox (By mouth) |
Drug Classes | Heavy Metal Chelator |
Drug Label | Exjade(deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125mg, 250mg, or 500mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its st... |
Active Ingredient | Deferasirox |
Dosage Form | Tablet, for suspension |
Route | Oral |
Strength | 250mg; 125mg; 500mg |
Market Status | Prescription |
Company | Novartis |
2 of 2 | |
---|---|
Drug Name | Exjade |
PubMed Health | Deferasirox (By mouth) |
Drug Classes | Heavy Metal Chelator |
Drug Label | Exjade(deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125mg, 250mg, or 500mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its st... |
Active Ingredient | Deferasirox |
Dosage Form | Tablet, for suspension |
Route | Oral |
Strength | 250mg; 125mg; 500mg |
Market Status | Prescription |
Company | Novartis |
GDUFA
DMF Review : Complete
Rev. Date : 2016-04-15
Pay. Date : 2016-03-17
DMF Number : 25733
Submission : 2012-01-26
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-20
Pay. Date : 2013-10-24
DMF Number : 27648
Submission : 2014-01-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25964
Submission : 2012-03-27
Status : Active
Type : II